These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26122704)

  • 1. A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
    Chen S; Zhang XJ; Xie WJ; Qiu HY; Liu H; Le WD
    CNS Neurosci Ther; 2015 Aug; 21(8):662-71. PubMed ID: 26122704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
    Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
    Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice.
    Rothe T; Deliano M; Wójtowicz AM; Dvorzhak A; Harnack D; Paul S; Vagner T; Melnick I; Stark H; Grantyn R
    Neuroscience; 2015 Dec; 311():519-38. PubMed ID: 26546830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Bailey CD; Rogers DA; Johnson GV; Hayden MR; Leavitt BR
    J Neurochem; 2005 Oct; 95(1):210-20. PubMed ID: 16181425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
    Ryskamp D; Wu J; Geva M; Kusko R; Grossman I; Hayden M; Bezprozvanny I
    Neurobiol Dis; 2017 Jan; 97(Pt A):46-59. PubMed ID: 27818324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
    Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
    J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
    Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
    J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
    Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
    BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Rogers DA; Lu G; Barakauskas VE; Barr AM; Honer WG; Hayden MR; Leavitt BR
    Exp Neurol; 2005 Dec; 196(2):266-72. PubMed ID: 16129433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAC128 mouse model of Huntington disease is protected against subtle chronic manganese (Mn)-induced behavioral and neuropathological changes.
    Wilcox JM; Pfalzer AC; Tienda AA; Debbiche IF; Cox EC; Totten MS; Erikson KM; Harrison FE; Bowman AB
    Neurotoxicology; 2021 Dec; 87():94-105. PubMed ID: 34543681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered palmitoylation and neuropathological deficits in mice lacking HIP14.
    Singaraja RR; Huang K; Sanders SS; Milnerwood AJ; Hines R; Lerch JP; Franciosi S; Drisdel RC; Vaid K; Young FB; Doty C; Wan J; Bissada N; Henkelman RM; Green WN; Davis NG; Raymond LA; Hayden MR
    Hum Mol Genet; 2011 Oct; 20(20):3899-909. PubMed ID: 21775500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolism.
    Madison JL; Wegrzynowicz M; Aschner M; Bowman AB
    PLoS One; 2012; 7(2):e31024. PubMed ID: 22363539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term atrazine exposure causes behavioral deficits and disrupts monoaminergic systems in male C57BL/6 mice.
    Lin Z; Dodd CA; Filipov NM
    Neurotoxicol Teratol; 2013; 39():26-35. PubMed ID: 23770127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acrylamide increases dopamine levels by affecting dopamine transport and metabolism related genes in the striatal dopaminergic system.
    Pan X; Guo X; Xiong F; Cheng G; Lu Q; Yan H
    Toxicol Lett; 2015 Jul; 236(1):60-8. PubMed ID: 25943760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manganese-induced hyperactivity and dopaminergic dysfunction depend on age, sex and YAC128 genotype.
    Wilcox JM; Consoli DC; Paffenroth KC; Spitznagel BD; Calipari ES; Bowman AB; Harrison FE
    Pharmacol Biochem Behav; 2022 Feb; 213():173337. PubMed ID: 35063467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
    Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
    Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
    Kolodziejczyk K; Raymond LA
    Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.